Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Cash & Current Investments (2019 - 2025)

Korro Bio (KRRO) has disclosed Cash & Current Investments for 6 consecutive years, with $92.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments rose 42.33% year-over-year to $92.5 million, compared with a TTM value of $92.5 million through Sep 2025, up 42.33%, and an annual FY2024 reading of $126.1 million, down 25.7% over the prior year.
  • Cash & Current Investments was $92.5 million for Q3 2025 at Korro Bio, down from $96.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $194.9 million in Q1 2021 and bottomed at $40.9 million in Q1 2023.
  • Average Cash & Current Investments over 5 years is $98.9 million, with a median of $93.0 million recorded in 2024.
  • The sharpest move saw Cash & Current Investments tumbled 74.91% in 2022, then soared 248.44% in 2024.
  • Year by year, Cash & Current Investments stood at $130.7 million in 2021, then plummeted by 57.73% to $55.2 million in 2022, then soared by 207.18% to $169.7 million in 2023, then dropped by 25.7% to $126.1 million in 2024, then dropped by 26.66% to $92.5 million in 2025.
  • Business Quant data shows Cash & Current Investments for KRRO at $92.5 million in Q3 2025, $96.4 million in Q2 2025, and $64.1 million in Q1 2025.